1-(4-methyl-benzo[1,3]dioxol-5-yl)-ethanone | 170570-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1-(4-methyl-benzo[1,3]dioxol-5-yl)-ethanone
• 英文别名: 1-(4-Methyl-benzo[1,3]dioxol-5-yl)-aethanon；5-acetyl-4-methyl-1,3-benzodioxole；1-(4-Methyl-1,3-benzodioxol-5-yl)ethanone
• CAS: 170570-86-2
• 化学式: C₁₀H₁₀O₃
• 分子量: 178.188
• InChiKey: RPQTVRVIXFJIFD-UHFFFAOYSA-N

物化性质

• 沸点：
  304.4±41.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-methyl-benzo[1,3]dioxol-5-yl)-ethanone 生成 4-[5-(4-methyl-1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
  参考文献：
  名称：

  Substituted pyrazolyl benzenesulfonamides for the treatment of

  摘要：

  描述了一类吡唑基苯磺酰胺化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式II定义：##STR1##或其药用可接受盐。

  公开号：

  US05760068A1
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 potassium permanganate 作用下， 生成 1-(4-methyl-benzo[1,3]dioxol-5-yl)-ethanone
  参考文献：
  名称：

  Gadamer; v. Bruchhausen, Archiv der Pharmazie, 1922, vol. 260, p. 108,111, 124

  摘要：

  DOI：

文献信息

• Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
  申请人：G.D. Searle & Co.

  公开号：US05756529A1

  公开（公告）日：1998-05-26

  A method of using pyrazolyl benzenesulfonamide compounds in treating inflammation and inflammation-related disorders in companion animals is disclosed.

  揭示了一种在治疗伴侣动物的炎症和与炎症相关的疾病中使用吡唑基苯磺酰胺化合物的方法。
• [EN] SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION<br/>[FR] BENZENESULFONAMIDES DE PYRAZOLYLE SUBSTITUES DESTINES AU TRAITEMENT DES INFLAMMATIONS
  申请人：G. D. SEARLE & CO.

  公开号：WO1995015316A1

  公开（公告）日：1995-06-08

  (EN) A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (II), whrein R2 is selected from hydrido, alkyl, haloalkyl, alkoxycarbonyl, cyano, cyanoalkyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, aminocarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl; wherein R3 is selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and wherein R4 is selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R4 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; provided R2 and R3 are not both hydrido; further provided that R2 is not carboxyl or methyl when R3 is hydrido and when R4 is phenyl; further provided that R4 is not triazolyl when R2 is methyl; further provided that R4 is not aralkenyl when R2 is carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that R4 is not phenyl when R2 is methyl and R3 is carboxyl; and further provided that R4 is not unsubstituted thienyl when R2 is trifluoromethyl; or a pharmaceutically acceptable salt thereof.(FR) L'invention se rapporte à une classe de composés de benzènesulfonamide de pyrazolyle utilisés pour traiter les inflammations et les troubles d'ordre inflammatoire. Les composés plus particulièrement étudiés répondent à la formule (II), dans laquelle R2 est choisi entre hydrido, alkyle, haloalkyle, alcoxycarbonyle, cyano, cyanoalkyle, carboxyle, aminocarbonyle, alkylaminocarbonyle, cycloalkylaminocarbonyle, arylaminocarbonyle, carboxyalkylaminocarbonyle, carboxyalkyle, aralcoxycarbonylalkylaminocarbonyle, aminocarbonylalkyle, alcoxycarbonylcyanoalcényle et hydroxyalkyle; R3 est choisi entre hydrido, alkyle, cyano, hydroxyalkyle, cycloalkyle, alkylsulfonyle et halo; R4 est choisi entre aralcényle, aryle, cycloalkyle, cycloalcényle et un groupe hétérocyclique; R4 pouvant être éventuellement substitué en une position apte à être substituée par un ou plusieurs radicaux choisis entre halo, alkylthio, alkylsulfonyle, cyano, nitro, haloalkyle, alkyle, hydroxyle, alcényle, hydroxyalkyle, carboxyle, cycloalkyle, alkylamino, dialkylamino, alcoxycarbonyle, aminocarbonyle, alcoxy, haloalcoxy, sulfamyle, un radical hétérocyclique et amino; à condition que R2 et R3 ne représentent pas tous deux hydrido; que R2 ne représente pas carboxyle ou méthyle quand R3 représente hydrido et quand R4 représente phényle; que R4 ne représente pas triazolyle quand R2 représente méthyle; que R4 ne représente pas aralcényle quand R2 représente carboxyle, aminocarbonyle ou éthoxycarbonyle; que R4 ne représente pas phényle quand R2 représente méthyle et R3 carbonyle; et que R4 ne représente pas thiényle non substitué lorsque R2 représente trifluorométhyle. L'invention se rapporte également à un sel pharmaceutiquement acceptable de ces composés.

  描述了一类用于治疗炎症和炎症相关疾病的吡唑基苯磺酰胺化合物。特别感兴趣的化合物由公式（II）定义，其中R2从氢基，烷基，卤代烷基，烷氧羰基，氰基，氰基烷基，羧基，氨基羰基，烷基氨基羰基，环烷基氨基羰基，芳基氨基羰基，羧基烷基氨基羰基，芳基氧羰基烷基氨基羰基，氨基羰基烷基，烷氧羰基氰基烯基和羟基中选择；其中R3从氢基，烷基，氰基，羟基烷基，环烷基，烷基磺酰和卤素中选择；其中R4从芳烯基，芳基，环烷基，环烯基和杂环中选择；其中R4在可取代位置上可用一个或多个基团进行取代，所述基团从卤素，烷基硫醇，烷基磺酰，氰基，硝基，卤代烷基，烷基，羟基，烯基，羟基烷基，羧基，环烷基，烷基氨基，二烷基氨基，烷氧羰基，氨基羰基，烷氧基，卤代烷氧基，磺酰胺基，杂环和氨基中选择；前提是R2和R3不都是氢基；进一步提供，当R3为氢基且R4为苯基时，R2不是羧基或甲基；进一步提供，当R2为甲基时，R4不是三唑基；进一步提供，当R2为羧基，氨基羰基或乙氧羰基时，R4不是芳烯基；进一步提供，当R2为甲基且R3为羧基时，R4不是苯基；进一步提供，当R2为三氟甲基时，R4不是未取代的噻吩基；或者其药学上可接受的盐。
• Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：US20040192930A1

  公开（公告）日：2004-09-30

  A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: 1 wherein R 2 is selected from hydrido, alkyl, haloalkyl, alkoxycaronyl, cyano, cyanoalkyl, carboxyl, aminocaronyl, alkylaminocarbonyl, cycloalklaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, amioncarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl; wherein R 3 is selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and wherein R 4 is selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R 4 is optionally substituted at a substitutable position with one or more radicals selected from halo alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; provided R 2 and R 3 are not both hydrido; further provided that R 2 is not carboxyl or methyl when R 3 is hydrido and when R 4 is phenyl; further provided that R 4 is not triazolyl when R 2 is methyl; further provided that R 4 is not arakenyl when R 2 is carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that R 4 is not phenyl when R 2 is methyl and R 3 is carboxyl; and further provided that R 4 is not unsubstituted thienyl when R 2 is trifluoromethyl; or a pharmaceutically-acceptable salt thereof.

  本文描述了一类吡唑基苯磺酰胺化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式II:1定义，其中R2从氢，烷基，卤代烷基，烷氧羰基，氰基，氰基烷基，羧基，氨基羧基，烷基氨基羰基，环烷氨基羰基，芳基氨基羰基，羧基烷基氨基羰基，羧基烷基，芳基氧羰基烷基氨基羰基，氨基羰基烷基，烷氧羰基氰基烯基和羟基烷基中选择；其中R3从氢，烷基，氰基，羟基烷基，环烷基，烷基磺酰和卤素中选择；其中R4从芳基烯基，芳基，环烷基，环烯基和杂环中选择；其中R4在可取代位置上可选择一个或多个基团进行取代，所述基团从卤代烷硫基，烷基磺酰，氰基，硝基，卤代烷基，烷基，羟基，烯基，羟基烷基，羧基，环烷基，烷基氨基，二烷基氨基，烷氧羰基，氨基羰基，烷氧基，卤代烷氧基，磺酰胺基，杂环和氨基中选择；前提是R2和R3不同时为氢；进一步提供R2在R3为氢且R4为苯基时不为羧基或甲基；进一步提供当R2为甲基时，R4不为三唑基；进一步提供当R2为羧基，氨基羰基或乙氧羰基时，R4不为芳基烯基；进一步提供当R2为甲基且R3为羧基时，R4不为苯基；进一步提供当R2为三氟甲基时，R4不为未取代的噻吩基；或其药学上可接受的盐。
• Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation
  申请人：Talley J. John

  公开号：US20050131050A1

  公开（公告）日：2005-06-16

  A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: wherein R 2 is selected from hydrido, alkyl, haloalkyl, alkoxycaronyl, cyano, cyanoalkyl, carboxyl, aminocaronyl, alkylaminocarbonyl, cycloalklaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, amioncarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl; wherein R 3 is selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and wherein R 4 is selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R 4 is optionally substituted at a substitutable position with one or more radicals selected from halo alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; provided R 2 and R 3 are not both hydrido; further provided that R 2 is not carboxyl or methyl when R 3 is hydrido and when R 4 is phenyl; further provided that R 4 is not triazolyl when R 2 is methyl; further provided that R 4 is not arakenyl when R 2 is carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that R 4 is not phenyl when R 2 is methyl and R 3 is carboxyl; and further provided that R 4 is not unsubstituted thienyl when R 2 is trifluoromethyl; or a pharmaceutically-acceptable salt thereof.

  本发明涉及一类吡唑基苯磺酰胺化合物，用于治疗炎症和炎症相关疾病。特别感兴趣的化合物由公式II定义：其中R2选自氢基，烷基，卤代烷基，烷氧羰基，氰基，氰基烷基，羧基，氨基羰基，烷基氨基羰基，环烷氨基羰基，芳基氨基羰基，羧基烷基氨基羰基，羧基烷基，芳基氧羰基烷基氨基羰基，氨基羰基烷基，烷氧羰基氰基烯基和羟基烷基；其中R3选自氢基，烷基，氰基，羟基烷基，环烷基，烷基磺酰和卤代基；其中R4选自芳基烯基，芳基，环烷基，环烯基和杂环基；其中R4在可取代位置上可选择地被一个或多个基团取代，所述基团选自卤代烷硫基，烷基磺酰基，氰基，硝基，卤代烷基，烷基，羟基，烯基，羟基烷基，羧基，环烷基，烷基氨基，二烷基氨基，烷氧羰基，氨基羰基，烷氧基，卤代烷氧基，磺酰胺基，杂环基和氨基；但要求R2和R3均不为氢基；进一步要求当R3为氢基且R4为苯基时，R2不为羧基或甲基；进一步要求当R2为甲基时，R4不为三唑基；进一步要求当R2为羧基、氨基羰基或乙氧羰基时，R4不为芳基烯基；进一步要求当R2为甲基且R3为羧基时，R4不为苯基；进一步要求当R2为三氟甲基时，R4不为未取代的噻吩基；或其药学上可接受的盐。
• Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation
  申请人：G.D. SEARLE & CO.

  公开号：EP0923933A1

  公开（公告）日：1999-06-23

  A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: wherein R2 is selected from hydrido, alkyl, haloalkyl, alkoxycarbonyl, cyano, cyanoalkyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, aminocarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl; wherein R3 is selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and wherein R4 is selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R4 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; provided R2 and R3 are not both hydrido; further provided that R2 is not carboxyl or methyl when R3 is hydrido and when R4 is phenyl; further provided that R4 is not triazolyl when R2 is methyl; further provided that R4 is not aralkenyl when R2 is carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that R4 is not phenyl when R2 is methyl and R3 is carboxyl; and further provided that R4 is not unsubstituted thienyl when R2 is trifluoromethyl; or a pharmaceutically-acceptable salt thereof.

  描述了一类用于治疗炎症和炎症相关疾病的吡唑苯磺酰胺化合物。特别感兴趣的化合物由式 II 定义： 其中 R2 选自肼基、烷基、卤代烷基、烷氧基羰基、氰基、氰基烷基、羧基、氨基羰基、烷基氨基羰基、环烷基氨基羰基、芳基氨基羰基、羧基烷基氨基羰基、羧基烷基、烷氧基羰基烷基氨基羰基、氨基羰基烷基、烷氧基羰基氰基烯基和羟基烷基；其中 R3 选自氢化吡啶、烷基、氰基、羟基烷基、环烷基、烷基磺酰基和卤素；以及 其中 R4 选自芳烯基、芳基、环烷基、环烯基和杂环基；其中 R4 在可被取代的位置上任选被一个或多个基团取代，这些基团选自卤、烷硫基、烷基磺酰基、氰基、硝基、卤代烷基、烷基、羟基、烯基、羟基烷基、羧基、环烷基、烷基氨基、二烷基氨基、烷氧基羰基、氨基羰基、烷氧基、卤代烷氧基、氨基磺酰基、杂环基和氨基；条件是 R2 和 R3 不同时为水合二酰胺基；进一步的条件是，当 R3 为水合二酰胺基和 R4 为苯基时，R2 不是羧基或甲基；进一步的条件是，当 R2 为甲基时，R4 不是三唑基； 当 R2 为羧基、氨基羰基或乙氧基羰基时，R4 不是芳烷基；当 R2 为甲基和 R3 为羧基时，R4 不是苯基；当 R2 为三氟甲基时，R4 不是未取代的噻吩基；或其药学上可接受的盐。